Fanconi Anemia Complementation Group G Protein
"Fanconi Anemia Complementation Group G Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A Fanconi anemia complementation group protein that undergoes PHOSPHORYLATION by CDC2 PROTEIN KINASE during MITOSIS. It forms a complex with other FANCONI ANEMIA PROTEINS and helps protect CELLS from DNA DAMAGE by genotoxic agents.
| Descriptor ID |
D052241
|
| MeSH Number(s) |
D12.776.313.906 D12.776.744.488
|
| Concept/Terms |
Fanconi Anemia Complementation Group G Protein- Fanconi Anemia Complementation Group G Protein
- XRCC9 Protein
- Fanconi Anemia Group G Protein
- X-Ray Repair Complementing Defective Repair In Chinese Hamster Cells 9 Protein
- X Ray Repair Complementing Defective Repair In Chinese Hamster Cells 9 Protein
- FANCG Protein
- Fanconi Anemia Group G Complementing Protein
|
Below are MeSH descriptors whose meaning is more general than "Fanconi Anemia Complementation Group G Protein".
Below are MeSH descriptors whose meaning is more specific than "Fanconi Anemia Complementation Group G Protein".
This graph shows the total number of publications written about "Fanconi Anemia Complementation Group G Protein" by people in this website by year, and whether "Fanconi Anemia Complementation Group G Protein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Fanconi Anemia Complementation Group G Protein" by people in Profiles.
-
Gallmeier E, Hucl T, Calhoun ES, Cunningham SC, Bunz F, Brody JR, Kern SE. Gene-specific selection against experimental fanconi anemia gene inactivation in human cancer. Cancer Biol Ther. 2007 May; 6(5):654-60.
-
Gallmeier E, Calhoun ES, Rago C, Brody JR, Cunningham SC, Hucl T, Gorospe M, Kohli M, Lengauer C, Kern SE. Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options. Gastroenterology. 2006 Jun; 130(7):2145-54.
-
van der Heijden MS, Brody JR, Dezentje DA, Gallmeier E, Cunningham SC, Swartz MJ, DeMarzo AM, Offerhaus GJ, Isacoff WH, Hruban RH, Kern SE. In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. Clin Cancer Res. 2005 Oct 15; 11(20):7508-15.
-
van der Heijden MS, Brody JR, Gallmeier E, Cunningham SC, Dezentje DA, Shen D, Hruban RH, Kern SE. Functional defects in the fanconi anemia pathway in pancreatic cancer cells. Am J Pathol. 2004 Aug; 165(2):651-7.
-
Rogers CD, van der Heijden MS, Brune K, Yeo CJ, Hruban RH, Kern SE, Goggins M. The genetics of FANCC and FANCG in familial pancreatic cancer. Cancer Biol Ther. 2004 Feb; 3(2):167-9.
-
van der Heijden MS, Yeo CJ, Hruban RH, Kern SE. Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res. 2003 May 15; 63(10):2585-8.